# A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

> **NCT01984242** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 305 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
- **DRUG:** Bevacizumab
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01984242
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-08
- **Primary completion:** 2016-10-17
- **Final completion:** 2019-01-08
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01984242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01984242, "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01984242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*